Search
Search
Top Menu
About
Philosophy
Vision & Strategy
Group Code of Conduct
Astellas Pharma Israel
Policies & Position Statements
Ethics & Compliance
Transparency
Making an Impact
Support for Medical Education
Top Menu
Therapy Areas
Therapy Areas
Urology
Oncology / Haematology
Transplantation
Astellas Products
BETMIGA™ (mirabegron)
MYCAMINE™ (micafungin sodium)
XTANDI™ (enzalutamide)
XOSPATA™ (gilteritinib)
ADVAGRAF™ (tacrolimus prolonged release)
PROGRAF™ (tacrolimus)
PADCEV™ (enfortumab vedotin)
Top Menu
Innovation
Clinical Trials
Astellas has established a website to disclose information obtained from Astellas-sponsored clinical trials…
לקריאה נוספת
R & D
Clinical Trials
Approach
Ethics & Principles
Pipeline
Investigator Sponsored Research
Top Menu
Sustainability
Access to Health
Advances continue to be made in technology and medicine that address unmet medical needs. However, there still remain barriers for many people…
לקריאה נוספת
Global Sustainability Policy
Sustainability Approach
Access to Health
Environment
Modern Slavery Act
Gender Pay Gap Report
Top Menu
News
Media Contacts
The Astellas Corporate Communications team will respond to calls and emails from journalists. For general media enquiries, please email contact_uk...
לקריאה נוספת
News
Media Contacts
Social Media Code of Conduct
Menu
menu
Common header menu
CONTACT US
CAREERS
WORLDWIDE
ISRAEL
WORLDWIDE - ISRAEL
English
עברית
Latest
Pause
Next
Astellas Pharma Israel
Find out more
Urology
Find out more
Oncology / Haematology
Find out more
1
2
3
Making an Impact
Find out more
Therapy Areas
Find out more
MAT-IL-NON-2023-00001
